double polymorphism
Diagnostic Testdiagnostic test
Other names: cases
NCT Number: NCT07330804
Cardiovascular disease (CVD) mortality is the leading cause of death in high-income countries (particularly the United States), accounting for 23.1% of all deaths It has been established over several decades that hypertension disproportionately affects African Americans, compared with Americans of European descent:Hypertension occurs more often, at an earlier age , with greater severity , and is associated with an approximately 3-fold higher probability of death .There is also poorer control of hypertension despit e similar treatment In African Americans, CVD morbidity and mortality are compounded by the higher prevalence of T2DM, obesity, CKD, stroke, and heart failure . Despite advances in the identification of risk factors and the availability of effective treatment in hypertension, CVD disparities, persist among African Americans and are expected to increase in the future, particularly in younger age groups. Although various environmental and social factors certainly contribute to these disparities, a genetic basis, involving numerous "candidate" genes, is most often asserted in the literature . One of these is the Corin gene (Pan et al, 2002) which codes for the Corin protein.The latter plays a pivotal role in cardiometabolic pathophysiology through its role in the activation of natriuretic peptides .Natriuretic peptides (ANP and BNP) have a major role in the regulation of blood pressure through their vasodilatory and diuretic action. They have a lusotropic action, inhibit the renin angiotensin system, and are involved in energy metabolism (increased lipolysis and insulin secretion). They also have an anti-fibrotic, anti-proliferative, anti-inflammatory and anti-thrombotic action.The Corin gene of 244109pb has many variants that produce an inefficient protein with the corollary of the appearance of metabolic and cardiovascular pathologies in the first rank of which the HTA, the cardiac insufficiency and the renal insufficiency .Recently, a double polymorphism of the Corin gene consisting of 2 SNPs (single nucleotide polymorphisms) on the same allele of the Corin gene (I555/P568) has been reported. This allele is present in the heterozygous state in 12% of African Americans but is extremely rare in Americans of European descent (<0.5%).This double polymorphism (I555/P568) has been shown to be responsible for an approximately 70% reduction in the ability of the mutated Corin protein to convert proANP or proBNP to the active form. In addition, the I555(P568) allele of Corin protein is associated with an increased risk of hypertension and concentric cardiac hypertrophy The corin allele (I555/P568) is reported to be associated with poorer response to validated heart failure therapy and a higher risk of death or hospitalization for heart failure .
In Guadeloupe, where the population is predominantly of African descent.Cardiovascular disease is the leading cause of mortality.The prevalence of hypertension is 39% and more than 50% after 50 years of age . It has increased by 10% in 10 years in Guadeloupe. In France, where the prevalence of hypertension is 31%, it has increased by only 5% over the same period.
Heart failure is the main cause of admission to the cardiological emergency room of the University Hospital (49%) with a mortality of 37% at 6 months. Hypertension is the first risk factor associated with heart failure (80%).To date, there are no studies on corin gene polymorphisms in Guadeloupe. Following the example of work already done in the African American population, we propose to study the role of the double polymorphism (I555/P568) in the determinism of hypertension in the population of African descent in Guadeloupe.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Medical practice KERIB, Petit-Bourg, Guadeloupe
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Case inclusion criteria
Control inclusion criteria:
Exclusion criteria
diagnostic test
Other names: cases
Time frame: At day 15
Time frame: At inclusion
Frequency of heart failure in cases and controls
Time frame: At Day 15
Frequency of renal failure in cases and
Time frame: At Day 15
natriuretic peptid assay in cases and controls
Time frame: At Day 15
creatinine clearance in MDRD in cases and controls
Time frame: At Day 15
Hb1AC measurement
Time frame: At Day 15
measurement
Time frame: At Day 15
measurement
Time frame: At inclusion
Body mass Index calculation measurement in cases and controls
Time frame: At inclusion
waist circumference measurement in cases and controls
Time frame: At 3 months for case, 12 months control
pourcentage
Time frame: At inclusion, or month 3 for case and month 12 for control
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
ratio
Time frame: At inclusion, or month 3 for case and month 12 for control
mm
Time frame: At inclusion, or month 3 for case and month 12 for control
ml
Time frame: At inclusion, or month 3 for case and month 12 for control
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
mV
Time frame: At inclusion, or month 3 for case and month 12 for control
mV
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de la Guadeloupe
Other
Acronym: HTAG-CORIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07420465
Cardiovascular Disease Risk, Cardiovascular Diseases
Accra, Ghana
View Trial DetailsNCT05765786
Adrenal Gland Diseases, Adrenocortical Hyperfunction
London, United Kingdom
View Trial DetailsNCT07267871
Cardiovascular Diseases, High Blood Pressure
San Francisco, California, United States
View Trial DetailsNCT06735599
Adult, Arterial Stiffness
Atlanta, Georgia, United States
View Trial Details